ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX) today announced that President and Chief Executive Officer John McDermott will make a presentation to the investment community at the Friedman Billings Ramsey 12th Annual Spring Investor Conference on Wednesday, May 28 at 2:15 p.m. Eastern time (11:15 a.m. Pacific time). This conference will be held at The Grand Hyatt New York. Interested investors may gain access to a live audio webcast and slide presentation via the Internet by visiting the Company�s Web site at www.endologix.com. Please go to the Interviews/Presentations page on the Investor Relations section of the Web site. The presentation will be available and archived on the Web site for 30 days. About Endologix Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix�s Web site at www.endologix.com.